Baltimore-based medical and biotechnology company Gliknik has secured $15 million in corporate funding, according to company database Crunchbase, topping the city’s recent funding headlines. The cash infusion was announced February 19 and financed by Pfizer.
According to its Crunchbase profile, "Gliknik, Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders. Its Immunomodulator Platform involves in off-the-shelf peptide drugs that increase CD4, CD8, and antibody immune responses against cancer; Stradomer Platform produces drugs designed to mimic the eficacy of pooled human intravenous immunoglobulin; and Stradobody Platform produces compounds that are similar to moncolonal antibodies for tumor cell killing. The company was founded in 2007 and is based in Baltimore, Maryland."
The 12-year-old company has raised seven previous funding rounds, including a $2.8 million round in 2013.
The round brings total funding raised by Baltimore companies in biotechnology over the past 90 days to $16 million. The local biotechnology industry has seen 18 funding rounds over the past year, securing a total of $50 million in venture funding.
In other local funding news, SaaS company Allovue announced a $4 million Series A funding round on February 11, financed by Macquarie Capital.
According to Crunchbase, "Our mission is to empower educators to strategically and equitably allocate resources to best support the needs of students."
Founded in 2013, the company has raised four previous rounds, including a $2 million Series A round in 2018.